Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension

Key Who May Qualify: - Ability to provide willing to sign a consent form and follow study instructions - 18 years of age or older - Diagnosis of open-angle glaucoma or ocular hypertension in both eyes - Qualifying IOPs across 2 visits following washout of IOP-lowering medication, if applicable - Qualifying best-corrected visual acuity BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) chart in study eye - Qualifying corneal endothelial cell density (CEDC) in the study eye Key Who Should NOT Join This Trial: - Pseudoexfoliation or pigment dispersion, narrow irido-corneal drainage angles, or existing peripheral anterior synechiae in the inferior angle either eye. - Advanced or severe glaucoma - Disqualifying central corneal thickness in either eye - Significant other ocular conditions that could prevent accurate assessment of IOP and corneal health - Uncontrolled medical conditions - Have previously received, any injectable glaucoma medication into the anterior chamber of the study eye - Have received intravitreal injections in the study eye within the last 3 months of the Screening Visit and anticipated need for an intravitreal injection during the course of the study - Unwilling or unable to discontinue, in either eye, soft contact lens wear at least 2 days and hard contact lens wear 1 week before scheduled study visits and on implant administration days Always talk to your doctor about whether this trial is right for you.